I already had considered everything you say. My point is that, at this point there is no possibility of the 2a data "going bad" because the trial completed. The extension doesn't really bear at all on the spectacular results that the originally planned trial produced. It was a complete success and that cannot change.
Now we move on to 2/3. As we continue to record more long-term results of the extension trial it will make approval smoother and quite possibly quicker.
Market Data 
Markets 
AI
